Related Experiment Video

Updated: Dec 14, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

3.0K

Pharmacotherapics Advice in Guidelines for COVID-19

Zhang-Ren Chen1, Ying Zhou1, Jin Liu1

  • 1Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China.

Frontiers in Pharmacology
|July 17, 2020
PubMed

Insights

This review summarizes COVID-19 pharmacotherapy guidelines and updates. It examines the efficacy and safety of anti-coronavirus disease 2019 drugs like chloroquine and tocilizumab.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Public Health

Background:

  • Coronavirus disease 2019 (COVID-19) rapidly emerged in late 2019, causing a global pandemic.
  • Limited effective treatments necessitated rapid development and guideline dissemination for COVID-19 pharmacotherapy.
  • International clinical trials informed treatment recommendations, leading to published guidelines from various countries and organizations.

Purpose of the Study:

  • To consolidate and analyze pharmacotherapy recommendations for COVID-19 from global guidelines.
  • To highlight recent updates and changes in COVID-19 treatment guidelines.
  • To critically review the efficacy and safety profiles of key anti-COVID-19 medications.

Main Methods:

  • Systematic review of national and international clinical guidelines for COVID-19 treatment.
  • Analysis of published data on the efficacy and safety of drugs recommended in guidelines.
  • Comparative assessment of pharmacotherapeutic strategies based on guideline updates.

Main Results:

  • Multiple pharmacotherapeutic options were proposed, including chloroquine and tocilizumab, with varying levels of evidence.
  • Guidelines evolved significantly between December 2019 and May 2020, reflecting emerging clinical data.
  • Efficacy and safety data for many anti-COVID-19 drugs remain under investigation, necessitating cautious application.

Conclusions:

  • Pharmacotherapy for COVID-19 is guided by evolving international recommendations.
  • Continuous evaluation of drug efficacy and safety is crucial for optimizing patient outcomes.
  • Further research is essential to establish definitive treatments for coronavirus disease 2019.

Keywords:
COVID-19SARS-CoV-2guidelinepharmacotherapypneumonia

More Related Videos

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.3K
Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic09:03

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Published on: November 7, 2020

5.3K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
646
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
137
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
102
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
109
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
189
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131